/
/
/

Senores Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
₹180 Cr₹175 Cr₹175 Cr₹162 Cr₹133 Cr₹114 Cr₹103 Cr₹101 Cr₹80 Cr₹102 Cr₹79 Cr
₹3 Cr₹18 Cr₹4 Cr₹5 Cr₹9 Cr₹12 Cr₹5 Cr₹2 Cr₹48 L₹2 Cr₹80 L
₹183 Cr₹193 Cr₹178 Cr₹167 Cr₹141 Cr₹126 Cr₹108 Cr₹102 Cr₹81 Cr₹104 Cr₹80 Cr
₹136 Cr₹137 Cr₹128 Cr₹120 Cr₹110 Cr₹100 Cr₹82 Cr₹81 Cr₹63 Cr₹84 Cr₹67 Cr
₹57 Cr₹65 Cr₹58 Cr₹55 Cr₹38 Cr₹31 Cr₹31 Cr₹25 Cr₹22 Cr₹24 Cr₹16 Cr
₹7 Cr₹8 Cr₹5 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹5 Cr₹5 Cr₹3 Cr₹2 Cr
₹39 Cr₹47 Cr₹45 Cr₹41 Cr₹26 Cr₹21 Cr₹20 Cr₹16 Cr₹13 Cr₹18 Cr₹10 Cr
₹30 Cr₹37 Cr₹34 Cr₹30 Cr₹21 Cr₹18 Cr₹16 Cr₹13 Cr₹11 Cr₹14 Cr₹7 Cr

Share Price Live Stats

Open (₹)1,377.10
Volume (₹)1.35 L
High (₹)1,417.90
Upper Circuit1,655.80
Low (₹)1,377.00
Lower Circuit1,104.00
Prev Close1,379.90
52W High (₹)1,599.00
Price1,383.40
52W Low (₹)662.45

Share Market Cap & Key Ratios Overview

M.Cap (₹)6354.24 Cr
Div. Yield (%)0.00
PE Ratio50.28
Debt to Equity0.35
Price to Book3.74
Book Value202.67
EPS (TTM)27.44
Face Value10.00
ROE (%)14.14

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
SENORESNSE
LTP
1W Low
1W High
Market cap (₹)
1865+27.7 (1.51%)
1832.20
1891.50
4,42,437Cr
9624+249 (2.66%)
9312.50
9624
2,48,054Cr
4985+145 (3.00%)
4848.50
4992
1,89,842Cr
1170.1+10.1 (0.87%)
1152.10
1178
1,15,810Cr
1383-11.5 (-0.82%)
1364.50
1405.20
1,11,565Cr
2034+80 (4.09%)
1963.80
2037.20
1,08,338Cr
2465+164.3 (7.14%)
2303
2493
1,02,410Cr
1211.2+26.2 (2.21%)
1185
1222
1,01,163Cr
1721.5-12.5 (-0.72%)
1689.30
1738.90
97,642Cr
2102.8+19.8 (0.95%)
2080
2135
96,950Cr
1383.4-19.2 (-1.37%)
1372.10
1417.90
6,354Cr

Key Highlights of Senores Pharmaceuticals Ltd’s P&L

In 2025-03-31, Senores Pharmaceuticals Ltd reported total revenue of ₹417.58Cr, compared with ₹217.34Cr in 2024-03-31, reflecting Senores Pharmaceuticals Ltd turnover.

Depreciation was ₹16.84Cr and finance costs were ₹21.55Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹70.57Cr in 2025-03-31 as compared to ₹24.94Cr in 2024-03-31.

Net Profit (PAT) was ₹58.56Cr in 2025-03-31 compared with ₹31.46Cr in 2024-03-31.

Earnings per share (EPS) were ₹12.72 in 2025-03-31, compared with ₹10.31 in 2024-03-31.